ESR1 and breast carcinoma: Various mechanisms account for the endocrine resistance in ER+ breast cancer, including mutations in ERα gene (ESR1), ERα post-translation modifications, and activation of the phosphatidylinositol 3-kinase (PI3K) pathway or PIK3CA activating mutations [6, 7].